Editorial
doi: 10.1200/JCO.2005.11.933.
Epub 2005 Feb 28.
Prostate cancer chemotherapy: emerging from the shadows
- PMID: 15738529
- DOI: 10.1200/JCO.2005.11.933
Item in Clipboard
Editorial
Prostate cancer chemotherapy: emerging from the shadows
J Clin Oncol.
.
No abstract available
Comment in
-
Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing?J Clin Oncol. 2005 Nov 1;23(31):8124-5; author reply 8125-6. doi: 10.1200/JCO.2005.03.2458. J Clin Oncol. 2005. PMID: 16258115 No abstract available.
Comment on
-
Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.J Clin Oncol. 2005 May 20;23(15):3343-51. doi: 10.1200/JCO.2005.12.187. Epub 2005 Feb 28. J Clin Oncol. 2005. PMID: 15738542 Clinical Trial.
Similar articles
-
[Treatment of locally spread prostate cancer].Duodecim. 2005;121(16):1779-82. Duodecim. 2005. PMID: 16268225 Review. Finnish. No abstract available.
-
Effectiveness of Maximal Androgen Blockade (MAB): illusion or reality?Can J Urol. 2005 Feb;12 Suppl 1:77-80. Can J Urol. 2005. PMID: 15780172 Review.
-
Chemotherapy for prostate cancer in senior adults: are we treating the elderly or the frail?Eur Urol. 2009 Jun;55(6):1310-2. doi: 10.1016/j.eururo.2008.08.065. Epub 2008 Sep 2. Eur Urol. 2009. PMID: 18778888 No abstract available.
-
Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.Eur Urol. 2009 Jun;55(6):1269-77. doi: 10.1016/j.eururo.2009.02.016. Epub 2009 Feb 21. Eur Urol. 2009. PMID: 19249153 Clinical Trial.
-
Therapies in development for castrate-resistant prostate cancer.Expert Rev Anticancer Ther. 2008 Feb;8(2):259-68. doi: 10.1586/14737140.8.2.259. Expert Rev Anticancer Ther. 2008. PMID: 18279066 Review.
Cited by
-
Targeting MMP-9, uPAR, and cathepsin B inhibits invasion, migration and activates apoptosis in prostate cancer cells.Cancer Gene Ther. 2010 Sep;17(9):599-613. doi: 10.1038/cgt.2010.16. Epub 2010 May 7. Cancer Gene Ther. 2010. PMID: 20448670 Free PMC article.
-
Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer.BMC Cancer. 2011 Jan 25;11:31. doi: 10.1186/1471-2407-11-31. BMC Cancer. 2011. PMID: 21266046 Free PMC article.
-
Dysfunctional transforming growth factor-beta receptor II accelerates prostate tumorigenesis in the TRAMP mouse model.Cancer Res. 2009 Sep 15;69(18):7366-74. doi: 10.1158/0008-5472.CAN-09-0758. Epub 2009 Sep 8. Cancer Res. 2009. PMID: 19738062 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
